BCL2L11 and ovarian cancer: Its recovered ability to target mRNAs after UCA1 upon downregulation (miR‐27a‐5p is expressed in the ovarian cancer cells we used in this study—data not shown) is therefore the main event leading to the upregulation of BIM, a proapoptotic member of the BCL2 family whose upregulation sensitizes cells to various chemotherapeutic agents [40].